Drug
Esketamine Nasal Spray
Esketamine Nasal Spray is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Total Trials
7
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Phase Distribution
Ph phase_1
1
14%
Ph phase_2
1
14%
Ph phase_3
2
29%
Ph not_applicable
2
29%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
2(33.3%)
N/ANon-phased studies
2(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
66.7%
4 of 6 finished
Non-Completion Rate
33.3%
2 ended early
Currently Active
0
trials recruiting
Total Trials
7
all time
Status Distribution
Completed(4)
Terminated(2)
Other(1)
Detailed Status
Completed4
Withdrawn2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 32 (33.3%)
N/A2 (33.3%)
Trials by Status
unknown114%
completed457%
withdrawn229%
Recent Activity
0 active trials
Showing 5 of 7
completedphase_1
KF2024#1-trial: Esketamine Interaction Study
NCT06726382
completednot_applicable
(GluEsk) Glutamate and Esketamine
NCT06432322
completedphase_3
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
NCT02782104
completed
Brain Network Dynamics of Depression During Esketamine Treatment
NCT06012916
withdrawnphase_2
Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
NCT04666623
Clinical Trials (7)
Showing 7 of 7 trials
NCT06726382Phase 1
KF2024#1-trial: Esketamine Interaction Study
NCT06432322Not Applicable
(GluEsk) Glutamate and Esketamine
NCT02782104Phase 3
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
NCT06012916
Brain Network Dynamics of Depression During Esketamine Treatment
NCT04666623Phase 2
Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
NCT04924257Phase 3
ECT vs. Esketamine
NCT04843462Not Applicable
Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7